Immunogenicity of COVID-19 vaccines in patients with cirrhosis: A meta-analysis

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 20(1)

Published: March 11, 2024

The immunogenicity of COVID-19 vaccines in patients with liver cirrhosis remains largely unknown. purpose this meta-analysis was to investigate the and compare humoral cellular immune responses following complete vaccination between healthy controls. A systematic literature search conducted PubMed, EMBASE, Web Science from 1 January 2020 22 August 2023. Sixteen studies 2127 were included. pooled seroconversion rate 92.4% (95% CI, 86.2%–96%, I2 = 90%) significant between-study heterogeneity. Moreover, elicited a higher response compensated as compared decompensated (RR 1.069, 95% 1.011–1.131, 17%, p .019). Additionally, 10 included for comparison analysis results showed that slightly lower controls 0.972, 0.955–0.989, 66%, .001). Meanwhile, RR vs. 0.678 0.563–0.817, 0, < .0001). Our demonstrated diminished cirrhosis. Patients particularly who have completed full-doses should receive continuous attention preemptive measures.

Language: Английский

A community study of neutralizing antibodies against SARS-CoV-2 in China

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Dec. 7, 2023

Background The immune background of the overall population before and after outbreak SARS-CoV-2 in China remains unexplored. And level neutralizing antibodies is a reliable indicator individual immunity. Objectives This study aimed to assess levels different groups during viral identify factors influencing these levels. Methods We measured 12,137 participants using COVID19 Neutralizing Antibody Detection kit. dynamics were analyzed generalized additive model, while linear model multi-factor analysis variance employed investigate factors. Additionally, statistical methods used compare antibody among subgroups real-world population. Results Participants who received booster doses exhibited significantly higher compared those only one or two (p&lt;0.001). Both elderly [22.55 (5.12, 62.03) IU/mL, 55%] minors [21.41 (8.15, 45.06) 56%] showed lower positivity rates young adults [29.30 (9.82, 188.08) 62%] Furthermore, HIV-positive group demonstrated slightly seropositivity rate healthy across three vaccination time points. Notably, months large-scale infection, both populations than previous record [300 (300, 300) 89%; 27.10 (8.77, 139.28) 60%], this difference was statistically significant. Conclusions Increasing vaccine dosage enhances levels, resulting greater longer-lasting Monitoring older individuals with AIDS crucial. generated from have not yet reached threshold for achieving herd immunity, exhibit following infection. These findings provide valuable insights guiding new strategies administration.

Language: Английский

Immunological Insights: A Multicenter Longitudinal Study on Humoral Response to COVID-19 Vaccines in Greece

Deleted Journal, Journal Year: 2024, Volume and Issue: 69(2), P. 101 - 113

Published: June 5, 2024

Vaccination has emerged as the most effective tool in battle against COVID-19. To optimize vaccination protocols, a deeper understanding of immune response to vaccination, including influential factors and its duration, is essential. This study aimed assess humoral vaccinated individuals with or without prior SARS-CoV-2 infection. A prospective observational was conducted across 14 private healthcare structures Greece. Anti-spike IgG titers were measured at different timepoints following initial booster doses BNT162b2, mRNA-1273, ChAdOx1 nCoV-19, Ad26.COV2.S vaccines. total 505 participants included first phase, evaluating after 311 involved second assessing effects vaccination. All vaccines elicited high anti-S initially, followed by subsequent decline that addressed The sustained up one year mRNA induced higher compared vector vaccines, mRNA-1273 eliciting than BNT162b2. resulted antibody natural infection alone; however, convalescent patients who received had significantly those vaccine previous Lower observed men older (>51.5 years old), well smokers, although rate lower these subgroups. These results underscore importance reveal potential influence age, gender, smoking habits, type on varying responses. Long-term monitoring persistence, evaluation cellular responses, assessment efficacy emerging variants should be considered enhance our immunity dynamics inform development deployment strategies.

Language: Английский